Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.94
+0.9%
$11.98
$10.45
$21.69
$4.93B0.62717,925 shs626,351 shs
Enovis Corporation stock logo
ENOV
Enovis
$34.56
+4.7%
$32.96
$28.83
$49.83
$1.97B1.7890,556 shs731,182 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$102.30
+0.8%
$96.00
$77.10
$163.71
$5.85B0.82740,102 shs478,289 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€24.97
+2.5%
€23.37
€17.12
€25.88
€7.56B0.55334,432 shs104,663 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.00%+6.14%+18.30%+26.59%-6.05%
Enovis Corporation stock logo
ENOV
Enovis
-1.84%+5.33%+3.90%+7.96%-26.34%
Glaukos Corporation stock logo
GKOS
Glaukos
-1.75%-1.67%+9.30%+24.26%-16.49%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-1.46%-1.14%+1.81%+30.13%+30.76%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.0959 of 5 stars
3.12.00.00.01.81.72.5
Enovis Corporation stock logo
ENOV
Enovis
3.5625 of 5 stars
3.43.00.00.03.21.71.9
Glaukos Corporation stock logo
GKOS
Glaukos
4.5323 of 5 stars
4.41.00.04.43.51.70.6
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.0844 of 5 stars
0.02.00.80.02.30.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.23
Hold$15.5811.79% Upside
Enovis Corporation stock logo
ENOV
Enovis
2.80
Moderate Buy$55.6060.88% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6731.64% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest ENOV, STVN, GKOS, and BLCO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$15.50 ➝ $16.00
7/8/2025
Enovis Corporation stock logo
ENOV
Enovis
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$48.00 ➝ $46.00
6/30/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $16.00
5/14/2025
Enovis Corporation stock logo
ENOV
Enovis
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $70.00
5/9/2025
Enovis Corporation stock logo
ENOV
Enovis
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$62.00 ➝ $55.00
5/9/2025
Enovis Corporation stock logo
ENOV
Enovis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$64.00 ➝ $57.00
5/6/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/6/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/2/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/2/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.03$1.88 per share7.41$18.57 per share0.75
Enovis Corporation stock logo
ENOV
Enovis
$2.11B0.94$19.75 per share1.75$45.10 per share0.77
Glaukos Corporation stock logo
GKOS
Glaukos
$404.52M14.45N/AN/A$13.91 per share7.35
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.12B6.72€0.77 per share32.58€5.02 per share4.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A14.521.56-7.50%2.62%1.28%7/30/2025 (Estimated)
Enovis Corporation stock logo
ENOV
Enovis
-$825.49M-$13.95N/A10.83N/A-37.65%5.99%3.44%8/6/2025 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€127.45M€0.5148.9643.052.3511.14%10.00%6.03%N/A

Latest ENOV, STVN, GKOS, and BLCO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.07N/AN/AN/A$1.25 billionN/A
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26N/AN/AN/A$115.49 millionN/A
5/8/2025Q1 2025
Enovis Corporation stock logo
ENOV
Enovis
$0.74$0.81+$0.07-$0.98$558.80 million$558.83 million
4/30/2025Q1 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
4/30/2025Q1 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Enovis Corporation stock logo
ENOV
Enovis
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years

Latest ENOV, STVN, GKOS, and BLCO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.74
1.56
0.96
Enovis Corporation stock logo
ENOV
Enovis
0.52
2.55
1.32
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
6.49
5.62
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.83
1.26

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Enovis Corporation stock logo
ENOV
Enovis
98.45%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.15%
Enovis Corporation stock logo
ENOV
Enovis
2.70%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.72 million353.19 millionOptionable
Enovis Corporation stock logo
ENOV
Enovis
7,36757.12 million55.58 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.14 million53.48 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
5,521302.84 millionN/AOptionable

Recent News About These Companies

STVN Stevanato Group S.p.A. - Seeking Alpha
Stevanato Group S.P.A. (IT0005452658.SG)
Stevanato: Recovery Underway, Buy Confirmed

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.94 +0.13 (+0.94%)
As of 03:29 PM Eastern

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Enovis stock logo

Enovis NYSE:ENOV

$34.56 +1.54 (+4.66%)
As of 03:29 PM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Glaukos stock logo

Glaukos NYSE:GKOS

$102.30 +0.84 (+0.83%)
As of 03:29 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€24.97 +0.62 (+2.55%)
As of 03:27 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.